-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s telavancin phosphate API has been approved.
Category:
Time：2023-04-10
On April 7, the active pharmaceutical ingredient tedizolid phosphate, submitted by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed formulations. This is the group’s fourth new API variety obtained this year.
On April 7, the active pharmaceutical ingredient tedizolid phosphate, submitted by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Fourth Pharmaceutical Group, was approved by the National Medical Products Administration and has been registered as an API for use in marketed formulations. This is the group’s fourth new API variety obtained this year.
It is reported that tedizolid phosphate is indicated for the treatment of acute bacterial skin and skin-structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, the Streptococcus pyogenes group (including Streptococcus pyogenes, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis.
In recent years, Shijiazhuang Sihua Pharmaceutical Group has actively implemented a “API + Finished Dosage Form” development strategy, aligning innovation chains with industrial chains. As a result, the efficiency of API development has continued to accelerate. Since 2023, the company has been granted approval for four distinctive APIs, significantly boosting the quality and efficiency of its finished dosage form business.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license